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Trisomy 8 (+8) is the most frequent numerical chromosome aberration in acute myeloid
leukemia (AML), occurring in approximately 9% of adult patients.1 In one-third of such
patients, +8 is the sole cytogenetic abnormality.1 These patients are mostly classified as
having an intermediate prognosis.1,2 The few available studies suggest that sole +8 AML is
molecularly heterogeneous,3-5 but the clinical impact of mutations remains to be established.
Moreover, although the biologic features of sole +8 AML have been investigated using
genome-wide gene-6,7 or microRNA-expression8 analyses, these studies included small
numbers of patients.
We report herein the molecular and clinical characterization of 80 adults with de novo AML
and sole +8 enrolled on Cancer and Leukemia Group B/Alliance clinical trials.
Methodological details are described in the Supplementary Information.
Ninety-four percent of the sole +8 AML patients harbored at least one mutation
(Supplementary Figure S1). The most frequently mutated genes were RUNX1 (32%), ASXL1
(29%), FLT3 (specifically FLT3-ITD: 29%), IDH2 (26%), DNMT3A (25%) and NPM1
(22.5%) (Table 1). Younger (<60 years) patients less often harbored mutations in RUNX1
(P=0.008), ASXL1 (P=0.002), IDH2 (P=0.04) and TET2 (P=0.001) than older (≥60 years)
patients.
We compared the mutational features of the +8 AML cohort with CN-AML patients, the
largest and molecularly best characterized cytogenetic subset of AML.1,2 Among younger
and older patients, those with sole +8 more often had mutations in ASXL1 (younger, P=0.04;
older, P<0.001) and RUNX1 (younger, P=0.08; older, P<0.001), and less often in NPM1
(younger and older, P<0.001) (Supplementary Table S1). Younger sole +8 patients also less
frequently had TET2 (P=0.002) and CEBPA (P=0.005) mutations than CN-AML patients.
Hence, particularly mutations in ASXL1 and RUNX1 associate with sole +8 AML. However,
no single mutation was as tightly associated with +8 AML as reported for AML with other
numeric aberrations, e.g., +11 and MLL-PTD,9 +13 and RUNX1 mutations.10 Future studies
may determine whether +8 favors acquisition of RUNX1 and ASXL1 mutations or whether
CN-AML with such mutations is prone to the gain of +8.
Patients included in the outcome analyses received cytarabine/daunorubicin-based induction
and consolidation, and no allogeneic hematopoietic stem-cell transplantation in first
complete remission (CR) (Supplementary Table S2). As in previous reports,1 the outcomes
of sole +8 AML patients were relatively poor; 64% achieved a CR and 5-year rates were 9%
for disease-free survival (DFS) and 15% for overall survival (OS) (Table 1). Notably, there
were no significant differences in CR rates, DFS or OS between younger and older patients
(Table 1), despite differences in treatment intensity. This is in contrast with the better
outcomes of younger patients previously observed in CN-AML2 and could be related to
differences in the mutation or gene-expression patterns (described below) between the
cytogenetic subsets.
To further characterize the outcome of sole +8 AML, we evaluated it in comparison with
CN-AML and in the context of the European LeukemiaNet (ELN) classification.2 Among
younger adults, sole +8 AML associated with worse CR rates (P=0.003), and shorter DFS
Becker et al. Page 2
Leukemia. Author manuscript; available in PMC 2015 March 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
(P=0.01) and OS (P=0.003) than CN-AML; among older individuals, sole +8 patients had
only a trend for shorter DFS (P=0.09) (Supplementary Table S3). In the ELN
recommendations,2 the Intermediate-II Genetic Group consists of two subsets: patients with
t(9;11)(p22;q23) and patients with cytogenetic aberrations not classified in the Favorable or
Adverse Genetic Groups, which also include sole +8. Thus, we compared the outcome of
sole +8 patients with that of t(9;11) patients and the remaining Intermediate-II patients
(Supplementary Table S3). Among younger adults, sole +8 patients had shorter DFS
(P=0.02) and OS (P=0.02) than t(9;11) patients, and worse CR rates (P=0.04) and OS
(P=0.05) but no significant differences in DFS compared with the remaining Intermediate-II
patients. Among older patients, there were no significant outcome differences between sole
+8, t(9;11) and the remaining Intermediate-II patients.
It is currently unknown whether molecular markers allow risk stratification in sole +8 AML.
Thus, we tested the prognostic significance of the various markers in multivariable models
(Table 2).
In younger patients, only BAALC expression impacted on CR attainment, with high BAALC
expressers having lower odds of achieving a CR (P=0.04). FLT3-ITD status was the only
variable associated with DFS; patients with FLT3-ITD had worse DFS than those without
(P=0.054). Both harboring FLT3-ITD (P=0.02) and being non-white (P=0.01) associated
with worse OS. Patients with FLT3-ITD had almost three times higher risk of death than
those without FLT3-ITD (Table 2). At 5 years, FLT3-ITD-positive patients had a DFS rate
of 0% and OS rate of 7% compared with the respective 22% and 31% for patients without
FLT3-ITD (DFS: P=0.054, OS: P=0.02; unadjusted rates; Supplementary Figure S2a,
Supplementary Table S4).
Among older patients, TET2 mutation status was the only significant marker for CR and
DFS (Table 2). Only 38% of the TET2-mutated patients achieved a CR compared with 80%
of wild-type TET2 patients (P=0.04), and the former had shorter DFS (P=0.048;
Supplementary Table S4). Both TET2 mutations (P=0.003) and wild-type RAS (P=0.03)
were associated with shorter OS (Table 2). TET2-mutated patients had almost fourfold
higher risk of death than those with wild-type TET2; the respective 3-year OS rates were 0%
and 25% (P=0.004; unadjusted rates; Supplementary Figure S2b, Supplementary Table S4).
The patient numbers were too small to formally investigate the significance of the combined
TET2 and RAS mutation status. However, three of the four older +8 patients with both wild-
type TET2 and RAS mutation were alive 3 years after diagnosis, whereas no patient with
mutated TET2 (and mostly wild-type RAS) was.
We previously reported that sole +8 AML associates with the overexpression of
chromosome 8-located genes due to their higher genomic dosage,6 and subsequent, small
studies made similar observations.7 The present study of a relatively large patient cohort
further characterizes this finding. We compared the gene-expression profiles between sole
+8 and CN-AML patients, and derived a signature comprising 452 genes significantly
upregulated and 329 downregulated in +8 AML (Supplementary Table S5). Consistent with
a gene dosage effect, 189 (42%) of the genes significantly upregulated in +8 AML were
located on chromosome 8 (Supplementary Figure S3a). Accordingly, in gene set enrichment
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analyses of the chromosome locations of all genes studied, chromosome 8 exhibited marked
upregulation in +8 AML compared with CN-AML (familywise error rate P<0.001;
normalized enrichment score 16.15). In a leave-one-out cross-validated analysis, 399 (92%)
of 434 patients were correctly classified as sole +8 or CN-AML based on the expression
pattern of the chromosome 8-located genes of the signature (80.6% sensitivity to correctly
predict the presence of +8, 94% specificity to correctly predict its absence). In line with our
earlier analysis of 41 genes in ten +8 AML patients,6 the upregulation of genes mapped to
chromosome 8 was evenly distributed along the entire chromosome (Supplementary Figure
S3b).
Among the most upregulated genes on chromosome 8 was BAALC. We originally identified
BAALC because of its high expression in +8 AML and subsequently described its high
expression as a prognostically adverse marker in CN-AML.11 As detailed above, higher
BAALC expression also associated with lower odds for CR attainment among younger sole
+8 patients, despite its overall high expression in sole +8 AML. A genomic neighbor of
BAALC, i.e., FZD6 (receptor of the Wnt signaling cascade) was also highly expressed in +8
AML. Strongly upregulated in +8 AML, but located on chromosome 21, was APP
(overexpressed in IDH2 R172-mutated CN-AML12 and AML with amplification of 21q-
material13). In gene ontology analyses of genes expressed ≥1.5-fold in sole +8 AML,
significantly overrepresented terms were response to chemical stimulus and extracellular
matrix organization (Supplementary Figure S4). Among the downregulated genes were
CD33 (target of gemtuzumab ozogamicin) and histone genes.
From the comparison of 354 mature microRNAs between sole +8 and CN-AML patients, we
derived a signature of 7 microRNAs – 5 upregulated and 2 downregulated in +8 AML
(Supplementary Table S6). In contrast to the protein-coding genes, none of the chromosome
8-located microRNAs that we studied was significantly upregulated in +8 AML
(Supplementary Table S7). Hence, it is currently uncertain whether microRNA expression is
affected by genomic dosage in the same manner as gene expression. MicroRNAs
overexpressed in +8 AML were miR-34b and miR-107 (activated by TP53),14,15 miR-370
(downregulates NF1, the deficiency of which causes hyperactive RAS signaling in myeloid
neoplasms)16 and miR-342 (upregulated by all-trans-retinoic acid in acute promyelocytic
leukemia).17
In summary, sole +8 AML is molecularly heterogeneous, with mutations in RUNX1, ASXL1,
IDH2, DNMT3A and NPM1, and FLT3-ITD being most frequent. Mutation frequencies
differ between +8 AML and CN-AML, and between younger and older sole +8 patients,
whereas the outcomes of younger and older sole +8 AML patients are only slightly different.
High BAALC expression and FLT3-ITD associated with worse outcomes among younger
and TET2 mutations and wild-type RAS among older sole +8 AML patients. Moreover, sole
+8 AML is characterized by distinct gene- and microRNA-expression patterns. The
increased dosage of chromosome 8-located genes leads to their overexpression, an effect not
observed for microRNAs. Our findings should be useful for the guidance of treatment
decisions and the development of new therapies that improve the poor outcome of patients
with sole +8 AML.
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Table 1
Pretreatment clinical and molecular characteristics and outcome of patients with de novo acute myeloid
leukemia and sole +8 and comparison by age group (<60 years vs ≥60 years)
Characteristic Sole +8 AML(n=80)
Sole +8 AML
<60 years
(n=40)
Sole +8 AML
≥60 years
(n=40) P 
f
Age, years -
 Median 59 43 71
 Range 18-84 18-59 60-84
Male sex, no. (%) 50 (63) 26 (65) 24 (60) 0.82
Race, no. (%) 0.85
 White 69 (87) 35 (90) 34 (85)
 Black or African American 8 (10) 3 (8) 5 (13)
 Other 2 (3) 1 (2) 1(2)
Hemoglobin, g/dL 0.64
 Median 9.2 9.2 9.1
 Range 5.0-15.8 5.0-15.8 5.3-14.1
Platelet count, × 109/L 0.63
 Median 46 49 41
 Range 5-233 11-148 5-233
WBC, × 109/L 0.003
 Median 8.9 20.7 4.2
 Range 0.6-302.3 0.6-302.3 0.8-187.0
Blood blasts, % 0.02
 Median 38 49 23
 Range 0-97 2-97 0-91
Bone marrow blasts, % 0.14
 Median 70 77 56
 Range 18-94 22-90 18-94
FAB, no. (%) a <0.001(M1/M2 vs
M4/M5)
 M0 3 (5) 1 (3) 2 (7)
 M1 9 (15) 2 (6) 7 (26)
 M2 17 (29) 6 (19) 11 (41)
 M4 9 (15) 5 (16) 4 (15)
 M5 19 (32) 17 (53) 2 (7)
 M6 2 (3) 1 (3) 1 (4)
Extramedullary involvement, no. (%) 15 (20) 9 (24) 6 (16) 0.57
 CNS 0 (0) 0 (0) 0 (0) NA
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Characteristic Sole +8 AML(n=80)
Sole +8 AML
<60 years
(n=40)
Sole +8 AML
≥60 years
(n=40) P 
f
 Hepatomegaly 2 (3) 2 (5) 0 (0) 0.24
 Splenomegaly 3 (4) 3 (8) 0 (0) 0.24
 Lymphadenopathy 5 (7) 4 (11) 1 (3) 0.19
 Skin infiltrates 6 (8) 1 (3) 5 (14) 0.11
 Gum hypertrophy 6 (8) 4 (11) 2 (5) 0.67
 Mediastinal mass 1 (1) 0 (0) 1 (3) 0.49
+8 metaphases in BM, no. (%)
 ≥ 80% 50 (63) 26 (65) 24 (60)
0.82
RUNX1, no. (%) 0.008
 Mutated 25 (32) 7 (18) 18 (46)
 Wild-type 54 (68) 33 (82) 21 (54)
ASXL1, no. (%) 0.002
(mutated vs
wild-type) Mutated 22 (29) 5 (13) 17 (46)
  c.1934dupG 10 1 9
  Other 12 4 8
 Wild-type 54 (71) 34 (87) 20 (54)
FLT3-ITD, no. (%) 0.14
 Positive 23 (29) 15 (38) 8 (20)
 Negative 57 (71) 25 (62) 32 (80)
IDH2, no. (%) 0.04
(mutated vs
wild-type) Mutated 21 (26) 6 (15) 15 (38)
  R140 mutated 13 4 9
  R172 mutated 8 2 6
 Wild-type 59 (74) 34 (85) 25 (62)
DNMT3A, no. (%) 0.58
(mutated vs
wild-type) Mutated 17 (25) 8 (22) 9 (29)
  R882 12 7 5
  Non-R882 5 1 4
 Wild-type 51 (75) 29 (78) 22 (71)
NPM1, no. (%) 0.18
 Mutated 18 (22.5) 12 (30) 6 (15)
 Wild-type 62 (77.5) 28 (70) 34 (85)
FLT3-TKD, no. (%) 0.54
 Positive 13 (17) 5 (13) 8 (21)
 Negative 65 (83) 34 (87) 31 (79)
IDH1, no. (%) 0.19
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Characteristic Sole +8 AML(n=80)
Sole +8 AML
<60 years
(n=40)
Sole +8 AML
≥60 years
(n=40) P 
f
 Mutated 11 (14) 3 (8) 8 (20)
 Wild-type 69 (86) 37 (92) 32 (80)
RAS, no. (%) 0.31
(mutated vs
wild-type) Mutated 10 (13) 3 (8) 7 (18)
  NRAS mutated 9 3 6
  KRAS mutated 1 0 1
 Wild-type 70 (87) 37 (92) 33 (82)
TET2, no. (%) 0.001
 Mutated 8 (11) 0 (0) 8 (24)
 Wild-type 64 (89) 39 (100) 25 (76)
CEBPA, no. (%) 0.20
(mutated vs
wild-type) Mutated 6 (8) 1 (3) 5 (13)
  Single mutated 4 1 3
  Double mutated 2 0 2
 Wild-type 74 (92) 39 (97) 35 (87)
WT1, no. (%) 1.00
 Mutated 3 (4) 2 (5) 1 (3)
 Wild-type 77 (96) 38 (95) 39 (97)
BAALC expression, no. (%) b 0.62
 High 33 (50) 16 (55) 17 (46)
 Low 33 (50) 13 (45) 20 (54)
miR-155 expression, no. (%) c 1.00
 High 31 (48) 14 (48) 17 (49)
 Low 33 (52) 15 (52) 18 (51)
miR-3151 expression, no. (%) b 1.00
 High 21 (50) 8 (50) 13 (50)
 Low 21 (50) 8 (50) 13 (50)
Endpoint
Sole +8
AML
(n=59) d
Sole +8 AML
<60 years
(n=30)
Sole +8 AML
≥60 years
(n=29)
OR/HR e
(95% CI)
P f
Complete remission 0.68(0.23-1.98) 0.47
No. in complete remission (%) 38 (64) 18 (60) 20 (69)
Disease-free survival 0.59(0.30-1.16) 0.13
No. of events 36 16 20
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Endpoint
Sole +8
AML
(n=59) d
Sole +8 AML
<60 years
(n=30)
Sole +8 AML
≥60 years
(n=29)
OR/HR e
(95% CI)
P f
Median, years 0.7 1.1 0.6
% Disease-free at 3 years (95% CI) 12 (4-25) 21 (6-42) 5 (0-21)
% Disease-free at 5 years (95% CI) 9 (2-21) 14 (3-35) 5 (0-21)
Overall survival 0.67(0.38-1.16) 0.15
No. of events 52 24 28
Median, years 1.3 1.5 1.2
% Alive at 3 years (95% CI) 23 (13-35) 29 (14-46) 17 (6-33)
% Alive at 5 years (95% CI) 15 (7-26) 19 (7-36) 10 (3-24)
Abbreviations: WBC, white blood count; FAB, French-American-British classification; NA, not applicable; FLT3-ITD, internal tandem duplication
of the FLT3 gene; FLT3-TKD, tyrosine kinase domain mutations of the FLT3 gene; OR, odds ratio; HR, hazard ratio; CI, confidence interval.
a
FAB morphology was centrally reviewed.
b
The median expression value was used as a cut point. It was calculated based on the expression levels assessed by RT-PCR.
c
The median expression value was used as a cut point. It was calculated based on the expression levels on the Affymetrix array.
dOf the 80 patients, 59 were evaluable for outcome. Pretreatment clinical and molecular characteristics of the patients included in outcome
analyses are provided in Supplementary Table S2.
e
Ratios are comparing outcome of patients <60 years vs ≥60 years.
f
P-values compare patients who are <60 years vs ≥60 years. For baseline continuous variables the Wilcoxon rank sum test was used, for baseline
categorical variables the Fisher’s exact test was used. For CR, the Wald test was used from the logistic regression model. For overall and disease-
free survival, the Wald test was used from the Cox regression models.
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